Clinical trial NCT03014726: ROBUST I Pilot Study, Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease
Official title: ROBUST I Pilot Study, ROBUST I Study, Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Stricture Urethra
Keywords: reduced urine flow rate
low peak flow rate
urinary tract infections
Lead sponsor: Urotronic Inc.
Sponsor class: INDUSTRY
First posted: 2017-01-09
Enrollment: 53
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Robust I study is a feasibility study for evaluating the safety and efficacy of DCB.

Detailed description: The study is designed to determine the safety and effectiveness for drug coated balloon (DCB).

Up to 50 subjects is planned to be enrolled and treated with the study device at up to 5 clinical sites outside of US. Due to significantly higher prevalence of strictures in men vs. women and the etiology of those strictures being different, the study will focus on male subjects with single anterior urethral stricture. Subjects will be followed up post-treatment to one year and then annually for up to 5 years. The annual follow up after the first year is optional.

Eligibility criteria: Inclusion Criteria:

1. Male subjects ≥ 18 years' old
2. Visual confirmation of stricture via cystoscopy or urethrogram
3. Single lesion anterior urethral stricture or bladder neck contracture, less than or equal to 2.0 cm
4. One to three (1-3) prior diagnosis and treatment of the same stricture (including self-catheterization) including DVIU (Direct Vision Internal Urethrotomy), but no prior urethroplasty
5. Significant symptoms of stricture such as frequency of urination, dysuria, urgency, hematuria, slow flow, feeling of incomplete emptying, recurrent UTI's.
6. IPSS score of 13 or higher
7. Lumen diameter \<12F by urethrogram
8. Able to complete validated questionnaire independently
9. Qmax \<10 ml/sec

Exclusion Criteria:

1. Strictures greater than 2.0 cm long.
2. Subjects that have more than 1 stricture.
3. Sensitivity to paclitaxel or on medication that may have negative interaction with paclitaxel
4. Subjects who have a suprapubic catheter and are unable to complete study required testing, such as uroflowmetry
5. Previous urethroplasty within the anterior urethra
6. Stricture due to bacterial urethritis or untreated gonorrhea
7. Stricture dilated or incised within the last 3 months
8. Presence of local adverse factors, including abnormal prostate making catheterization difficult, urethral false passage or fistula.
9. Presence of signs of obstructive voiding symptoms not directly attributable to the stricture such as BPH at the discretion of the clinical investigator
10. Previous radical prostatectomy
11. Previous pelvic radiation
12. Diagnosed kidney, bladder, urethral or ureteral stones or active stone passage in the past 6 months.
13. Diagnosed with chronic renal failure unless under hemodialysis or has a serum creatinine level greater than 2 mg/dL
14. Use of alpha blockers, beta blockers, OAB (Overactive Bladder) medication, anticonvulsants (drugs that prevent or reduce the severity and frequency of seizures), and antispasmodics where the dose is not stable. (Stable dose is defined as having the same medication and dose in the last six months.)
15. Use of Botox (onabotulinumtoxinA) in urinary system within the last 12 months

Primary outcomes:
measure: Rate of Treatment Related Serious Complication
timeFrame: 90 days post-procedure
Secondary outcomes:
measure: Stricture Recurrence Rate
timeFrame: 90 days post-procedure
Other outcomes:
Locations:
city: Brooklyn Park
country: United States
facility: Libra Medical Inc
state: Minnesota
Study officials:
affiliation: Urotronic (Study Sponsor)
name: Ian Schorn
role: STUDY_DIRECTOR
References: